Symbols

QTTB

Q32 Bio·NASDAQ

--(--)

Signals Analysis

Bullish signal 5

Bearish signal 0

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

Significant Net Income Growth

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About QTTB

Q32 Bio Inc.

A biotechnology company focused on treating autoimmune and inflammatory diseases

Industry

Biological Technology

Established Date

Listing Date

03/28/2018

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.q32bio.com

Security Type

Common stock

Office address

830 Winter Street, Waltham, MA 02451

Business

Introduction

Q32 Bio Inc., incorporated in 2015 under the laws of the State of Delaware, is a genetic medicine company dedicated to improving the lives of patients with rare genetic diseases and addressing significant unmet medical needs by treating the underlying causes of the disease. The Company's proprietary platform is designed to utilize adeno-associated virus vectors, or AAVHSCs, derived from human hematopoietic stem cells to accurately and efficiently deliver in vivo genetic medicines in a wide range of genetic diseases through gene therapy or nuclease gene editing. The unique properties of its 15 new AAVHSC proprietary kits enable it to focus on gene editing methods called gene correction, either by replacing entire disease genes in the genome with complete functional copies or precisely repairing individual mutated nucleotides by utilizing homologous recombination of naturally occurring DNA repair processes or HR.

Company Financials

EPS

QTTB has released its 2025 Q4 earnings. EPS was reported at 4.58, versus the expected -0.79, beating expectations. The chart below visualizes how QTTB has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

QTTB has released its 2025 Q4 earnings report, with revenue of 53.74M, reflecting a YoY change of NaN%, and net profit of 57.73M, showing a YoY change of 506.86%. The Sankey diagram below clearly presents QTTB's revenue sources and cost distribution.